#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Hepatocellular carcinoma Dementia Alzheimer's type Asthma Dermatitis atopic Breast cancer metastatic Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Inclusion body myositis Dermatomyositis Peripheral T-cell lymphoma unspecified Prophylaxis against transplant rejection Anti-myelin-associated glycoprotein antibodies positive Adrenoleukodystrophy Chronic lymphocytic leukaemia Philadelphia chromosome positive Neoplasm malignant Squamous cell carcinoma of the oral cavity Rectal cancer Arterial disorder Ureteric cancer Retinopathy of prematurity Pemphigoid More trials…

    Learn about Rare Diseases

    Nephroblastoma – Diagnostics Richter’s syndrome Hereditary hypophosphataemic rickets – Diagnostics Hereditary neuropathic amyloidosis Malignant fibrous histiocytoma – Basic Information Langerhans’ cell histiocytosis – Trials in Disease CADASIL Small intestine leiomyosarcoma – Life with Disease Phenylketonuria Lennox-Gastaut syndrome – Life with Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Anthoxanthum Odoratum Melphalan Flufenamide Nilutamide Pitolisant Chlorpromazine Hydrochloride ANTIMETABOLITES 534 Rucaparib Ixazomib Citrate Palonosetron Edg-5506 Timothy Grass Pollen Extract Human Coagulation Factor Ix Albaconazole Ampicillin ADX-038 RNMB3 SC0062 Antiemetics And Antinauseants Potassium Oxybate More therapies…

    Learn about Your Condition

    Status epilepticus Morning sickness Diphtheria Pancreatic carcinoma recurrent Round cell liposarcoma Nephroblastoma Skin disorder Brain neoplasm malignant Hyperhidrosis Inflammatory bowel disease Oesophagectomy Hypophosphatasia Alopecia areata Erythema Glanzmann's disease More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Dermatomyositis

  • Study on the Long-Term Safety of Dazukibart in Patients with Idiopathic Inflammatory Myopathies, Including Dermatomyositis and Polymyositis

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Dermatomyositis
    • Idiopathic inflammatory myopathy
    • Polymyositis
    Investigated Drugs:
    • Azathioprine
    • Betamethasone
    • Budesonide
    Bulgaria Hungary Italy Poland Spain Sweden

  • Study on Anifrolumab for Adults with Polymyositis or Dermatomyositis

    Recruiting

    3 1 1
    Investigated Drugs:
    • Anifrolumab
    Austria Belgium Bulgaria Czechia Denmark France +7

  • Study on Baricitinib for Patients with Relapsing or Naïve Dermatomyositis

    Recruiting

    4 1 1
    Investigated Diseases:
    • Dermatomyositis
    Investigated Drugs:
    • Baricitinib
    France

  • Study on Upadacitinib for Patients with Idiopathic Inflammatory Myopathies After Stopping IVIG

    Recruiting

    2 1 1
    Investigated Diseases:
    • Antisynthetase syndrome
    • Necrotising myositis
    • Immune-mediated myositis
    Investigated Drugs:
    • Upadacitinib
    Austria

  • Study on Low-Dose Aldesleukin for Patients with Pemphigus, Mucous Membrane Pemphigoid, Polymyositis, Dermatomyositis, and Primary Sclerosing Cholangitis

    Recruiting

    2 1 1
    Investigated Diseases:
    • Mucous membrane pemphigoid
    • Pemphigus
    • Cholangitis sclerosing
    Investigated Drugs:
    • Aldesleukin
    • Glucose
    Germany

  • Study on the Effectiveness of Dazukibart in Adults with Active Dermatomyositis or Polymyositis

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Dermatomyositis
    • Polymyositis
    Investigated Drugs:
    • Humanised Igg1K Monoclonal Antibody Against Interferon Beta
    • Hydroxychloroquine Sulfate
    • Proguanil Hydrochloride
    Belgium Bulgaria France Germany Hungary Italy +4
1 2 3
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!